home.aspx

 
.

MANAGING MULTIPLE BIOMARKER THERAPEUTIC DEVELOPMENT

July 16, 2019
USA (United States of America)
For the past two decades, the paradigm in the field has been “one biomarker, one drug,” leading to the development of many targeted therapies and companion diagnostics. As molecular profiling of various cancer types expands, we imagine the use of multiple biomarkers for a combination therapy, like a targeted therapy and immunotherapy together, or even for a monotherapy.